Equitec Proprietary Markets’s PharmaCyte Biotech PMCB Stock Holding History

Equitec Proprietary Markets’s Portfolio PMCB Stock Details PMCB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$17.1K	Hold	22,227	–	–	﹤0.01%	73
2026 Q1	$14.8K	Hold	22,227	–	–	0.01%	55
2025 Q4	$16.1K	Sell	22,227 -60,500	-73%	-$54.5K	0.01%	57
2025 Q3	$80.2K	Hold	82,727	–	–	0.02%	41
2025 Q2	$90.2K	Hold	82,727	–	–	0.09%	37
2025 Q1	$103K	Hold	82,727	–	–	0.07%	36
2024 Q4	$130K	Hold	82,727	–	–	0.13%	28
2024 Q3	$158K	Hold	82,727	–	–	0.13%	28
2024 Q2	$162K	Hold	82,727	–	–	0.21%	32
2024 Q1	$196K	Hold	82,727	–	–	0.12%	38
2023 Q4	$179K	Hold	82,727	–	–	0.13%	41
2023 Q3	$174K	Buy	82,727 +21,312	+35%	+$54.3K	0.04%	55
2023 Q2	$176K	Sell	61,415 -269,279	-81%	-$808K	0.05%	65
2023 Q1	$962K	Hold	330,694	–	–	0.45%	34
2022 Q4	$969K	Hold	330,694	–	–	0.31%	39
2022 Q3	$794K	Sell	330,694 -12,300	-4%	-$31.1K	0.21%	57
2022 Q2	$768K	Buy	342,994 +33,700	+11%	+$73.7K	0.22%	60
2022 Q1	$711K	Buy	309,294 +50,600	+20%	+$112K	0.16%	52
2021 Q4	$647K	Buy	+258,694	New	+$713K	0.09%	72

Other funds holding PMCB

Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return

BFSG LLC Irvine, California $1.13B AUM 29.95% 1-Year Est. Return

Financial Consulate Hunt Valley, Maryland $899M AUM 20.23% 1-Year Est. Return

Equitec Proprietary Markets's PMCB Position: Q2 2026 in Review

Equitec Proprietary Markets held its PharmaCyte Biotech (PMCB) position steady in Q2 2026 at 22,227 shares worth $17.1K. The position accounts for ﹤0.01% of the portfolio, ranked #73.

Equitec Proprietary Markets first reported a position in PMCB in Q4 2021 and has held it in 19 quarters since. The position peaked at $969K in Q4 2022. 5 funds tracked by Wall St. Rank hold PMCB as of Q2 2026.

Equitec Proprietary Markets held 22,227 shares of PharmaCyte Biotech worth $17.1K as of Q2 2026.
Equitec Proprietary Markets left its PharmaCyte Biotech share count unchanged in Q2 2026.
PharmaCyte Biotech made up ﹤0.01% of Equitec Proprietary Markets's portfolio in Q2 2026, its #73 holding.
Equitec Proprietary Markets first reported a position in PharmaCyte Biotech in Q4 2021 and has held it in 19 quarters since.
Equitec Proprietary Markets's PharmaCyte Biotech position peaked at $969K in Q4 2022.
5 funds tracked by Wall St. Rank held PharmaCyte Biotech as of Q2 2026.

Based on Equitec Proprietary Markets's 13F filing for Q2 2026, filed 20 Jul 2026.